Zimmer Biomet (ZBH) Transformation is Progressing, Will Divesting Dental Be Next? - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst David Lewis reiterated an Overweight rating and $150.00 price target on Zimmer Biomet (NYSE: ZBH) noting that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
